Intracoronary Compared With Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: Cardiac Magnetic Resonance Substudy of the AIDA STEMI Trial

摘要: Objectives The aim of the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction) cardiac magnetic resonance (CMR) substudy was to investigate potential benefits intracoronary versus intravenous abciximab bolus administration on infarct size and reperfusion injury ST-segment elevation myocardial infarction. Background trial randomized 2,065 patients or found similar rates major adverse events at 90 days with significantly less congestive heart failure group. CMR can directly visualize damage injury, thereby providing mechanistic pathophysiological insights. Methods We enrolled 795 substudy. completed within 1 week after Central core laboratory–masked analyses for quantified ventricular function, volumes, size, microvascular obstruction, hemorrhage, salvage were performed. Results area risk (p = 0.97) final (16% [interquartile range: 9% 25%] 17% 8% 25%], p 0.52) did not differ between groups. Consequently, index (52 35 69] 50 29 69], 0.25). There also no differences obstruction 0.19), intramyocardial hemorrhage ejection fraction 0.95) both treatment Patients whom occurred had larger infarcts, salvage, more pronounced dysfunction. Conclusions This largest multicenter study infarction date demonstrates benefit and/or injury. Infarct determined by associated events. Infarction [AIDA STEMI]; NCT00712101 )